Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).
Minneapolis Heart Institute Foundation
81 participants
Aug 3, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
Eligibility
Inclusion Criteria4
- Patients with their first STEMI (>18 years) who underwent successful primary PCI and able to give informed consent
- At least mild LV dysfunction (LVEF < 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
- Infarct size that is > 10% of LV mass
- The presence of MVO that is > 10% of infarct size
Exclusion Criteria13
- Contraindication to cardiac MRI
- Life expectancy < 1 year
- Previous CABG or Valve Surgery
- Previous STEMI
- Pregnant or planning to become pregnant or lactating women
- Cardiogenic shock (not resolved)
- Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)
- GFR<30 ml/min/1.73m2 or end-stage renal disease on dialysis
- Type 1 diabetes mellitus or history of diabetic ketoacidosis
- Type I or II diabetes with insulin use
- Prior intolerance of SGLT2 inhibitors
- Current use of SGLT2 inhibitors (randomized patients only)
- Contraindications to gadolinium
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
SGLT2 inhibitor once daily for six months
Placebo once daily for six months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05305911